Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...
4d
Hosted on MSNAllurion’s weight loss balloon back on French marketAllurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...
Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...
NATICK, Mass., January 24, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...
The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the ...
Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...
Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...
Allurion Technologies (ALUR) announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, ...
Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss Allurion Technologies, Inc. (“Allurion” or the “Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results